You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-CD3

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Advanced/Metastatic Solid Tumors Trial in Frankston, Nedlands, Beijing (EMB07)

Not yet recruiting
  • Advanced/Metastatic Solid Tumors
  • Frankston, Victoria, Australia
  • +2 more
Nov 3, 2022

Urinary Bladder Tumors Trial in München (Catumaxomab)

Recruiting
  • Urinary Bladder Neoplasms
  • München, Germany
    Urologie Planegg
Apr 4, 2022

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)

Active, not recruiting
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Indianapolis, Indiana
  • +6 more
Aug 16, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Recurrent or Metastatic Solid Tumors Trial (Recombinant Anti-EpCAM-CD3 Antibody Injection)

Not yet recruiting
  • Recurrent or Metastatic Solid Tumors
  • Recombinant Anti-EpCAM-CD3 Antibody Injection
  • (no location specified)
Oct 17, 2023

Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a Trial in Heidelberg (Standard, Experimental)

Recruiting
  • Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
  • Standard
  • Experimental
  • Heidelberg, Germany
    University Hospital Heidelberg
Jul 10, 2022

Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis Trial (Intranasal Foralumab

Withdrawn
  • Primary Progressive Multiple Sclerosis
  • +2 more
  • Intranasal Foralumab Solution
  • Placebo
  • (no location specified)
Feb 14, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

HER2-Positive Solid Tumors Trial (Chort 1 of M802, Chort 2 of M802, Cohort 3 of M802)

Not yet recruiting
  • HER2-Positive Solid Tumors
  • Chort 1 of M802
  • +7 more
  • (no location specified)
Jul 28, 2021

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

B Acute Lymphoblastic Leukemia Trial in Duarte (drug, procedure, other)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Autologous Anti-CD19 CAR-expressing T Lymphocytes
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • FLT3 Ligand (CDX-301)
  • +2 more
  • Bronx, New York
    Albert Einstein College of Medicine
Jul 18, 2022

Type 1 Diabetes Trial in Atlanta (Teplizumab)

Terminated
  • Type 1 Diabetes Mellitus
  • Atlanta, Georgia
    Atlanta Diabetes Associates
Feb 4, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in New York, Charlottesville

Active, not recruiting
  • Pancreatic Cancer
  • +3 more
  • anti-EGFR-bispecific antibody armed activated T-cells
  • New York, New York
  • +1 more
Oct 7, 2021

Healthy Adults Trial in Créteil (Solo 0.3 group, Solo 1 group, Solo 3 group)

Recruiting
  • Healthy Adults
  • Solo 0.3 group
  • +5 more
  • Créteil, France
  • +2 more
Sep 9, 2022

Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
Jul 18, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

B-precursor Acute Lymphoblastic Leukemia, ALL, GNR-084 Trial in Moscow, Saint Petersburg (GNR-084, 0.01 ng/kg, GNR-084, 0.1

Recruiting
  • B-precursor Acute Lymphoblastic Leukemia
  • +2 more
  • GNR-084, 0.01 ng/kg
  • +5 more
  • Moscow, Russian Federation
  • +2 more
Oct 25, 2021